Is TIMP-1 immunoreactivity alone or in combination with other markers a predictor of benefit from anthracyclines in the BR9601 adjuvant breast cancer chemotherapy trial?

por Munro, Alison F, Bartels, Annette, Balslev, Eva, Twelves, Christopher J, Cameron, David A, Brünner, Nils, Bartlett, John MS
Publicado 2013

Characterizing and quantifying the effects of breast cancer therapy using mathematical modeling

por Gregory, Walter M., Twelves, Christopher J., Bell, Richard, Smye, Stephen W., Howard, Dena R., Coleman, Robert E., Cameron, David A.
Publicado 2016

Downregulation of histone H2A and H2B pathways is associated with anthracycline sensitivity in breast cancer

por Braunstein, Marsela, Liao, Linda, Lyttle, Nicola, Lobo, Nazleen, Taylor, Karen J., Krzyzanowski, Paul M., Kalatskaya, Irina, Yao, Cindy Q., Stein, Lincoln D., Boutros, Paul C., Twelves, Christopher J., Marcellus, Richard, Bartlett, John M. S., Spears, Melanie
Publicado 2016